Experimental cell therapy aims to reset immune system in Tough-to-Treat lupus
Disease control
Not yet recruiting
This early-stage study is testing a personalized cell therapy called C-CAR168 for people with severe lupus kidney disease that hasn't improved with standard treatments. Doctors will collect a patient's own immune cells, modify them to target specific markers on harmful immune cel…
Phase: PHASE1, PHASE2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC